Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Net Profit Margin
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Pfizer Inc., net profit margin, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The financial performance over the analyzed periods reveals notable fluctuations in both net income attributable and revenues, alongside variations in net profit margin percentage.

Net income attributable to Pfizer Inc.
Net income figures exhibited significant volatility throughout the timeline with pronounced peaks and troughs. Early years saw a strong increase, reaching a peak in 2006 with approximately 19,337 million US dollars, followed by a notable decline in subsequent years. Another substantial peak occurred in 2013, with net income surpassing 22,003 million US dollars. Afterward, net income generally ranged between approximately 7,000 and 11,000 million US dollars for several years. A distinctly higher value occurred in 2017, strongly rising again in 2018 and peaking dramatically in 2021 with 31,372 million US dollars. However, the most recent years showed a sharp decline, falling to around 2,119 million in 2023 before increasing again to 8,031 million in 2024.
Revenues
Revenues initially displayed moderate variation, mostly ranging between 48,000 and 68,000 million US dollars from 2005 through 2011. From 2012 onward, revenues showed more pronounced fluctuations, with a significant decline seen in 2015–2016, before rising substantially to 82,145 million in 2021 and further to a maximum of 101,175 million in 2022. However, by 2023 the revenues had dropped back to 59,553 million and slightly recovered to 63,627 million in 2024.
Net profit margin
Net profit margin as a percentage experienced considerable variation, reflecting the volatility in net income relative to revenues. The margin fluctuated widely early on, with an especially high margin of nearly 40% in 2006 and a similarly elevated 42.65% in 2013. Other years saw margins closer to a range between roughly 12% and 31%. Recent years again demonstrated notable fluctuation, with profit margins falling to as low as around 3.56% in 2023, before recovering to approximately 12.62% in 2024.

Overall, the data points to a company with periods of highly variable profitability and revenue, including occasional peaks that may correspond to extraordinary or cyclical factors. The marked fluctuations in profit margin imply varying operational efficiency or external conditions influencing profitability. The recent downward trend in both net income and margin despite relatively stable revenues warrants attention for potential impacts on financial health and future planning.


Comparison to Competitors

Pfizer Inc., net profit margin, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Pfizer Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)